BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Axelrad J, Kriplani A, Ozbek U, Harpaz N, Colombel JF, Itzkowitz S, Holcombe RF, Ang C. Chemotherapy Tolerance and Oncologic Outcomes in Patients With Colorectal Cancer With and Without Inflammatory Bowel Disease. Clin Colorectal Cancer 2017;16:e205-10. [PMID: 27742264 DOI: 10.1016/j.clcc.2016.09.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Sun F, Liang W, Tang K, Hong M, Qian J. Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer. PeerJ 2019;7:e7451. [PMID: 31523496 DOI: 10.7717/peerj.7451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
2 Kimmel J, Axelrad J. The Complex Interplay Between Inflammatory Bowel Disease and Malignancy. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-0747-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Yaeger R, Paroder V, Bates DDB, Capanu M, Chou J, Tang L, Chatila W, Schultz N, Hersch J, Kelsen D. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. Clin Colorectal Cancer 2020;19:e151-6. [PMID: 32798155 DOI: 10.1016/j.clcc.2020.02.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ueda T, Tanaka T, Yokoyama T, Sadamitsu T, Koyama F, Fujii H, Yoshimura A. Long-Term Survival After Pelvic Exenteration for Locally Recurrent Rectal Cancer Associated With Crohn's Disease With, Adjuvant Chemotherapy, and Immunosuppressive Therapy. ACG Case Rep J 2020;7:e00374. [PMID: 32548201 DOI: 10.14309/crj.0000000000000374] [Reference Citation Analysis]
5 Peixoto RD, Ferreira AR, Cleary JM, Fogacci JP, Vasconcelos JP, Jácome AA. Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy. J Gastrointest Cancer 2022. [PMID: 35288863 DOI: 10.1007/s12029-022-00816-0] [Reference Citation Analysis]
6 Fohlen A, Bordji K, Assenat E, Gongora C, Bazille C, Boulonnais J, Naveau M, Breuil C, Pérès EA, Bernaudin M, Guiu B. Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. Pharmaceuticals (Basel) 2021;14:639. [PMID: 34358065 DOI: 10.3390/ph14070639] [Reference Citation Analysis]
7 Bogach J, Pond G, Eskicioglu C, Seow H. Age-Related Survival Differences in Patients With Inflammatory Bowel Disease–Associated Colorectal Cancer: A Population-Based Cohort Study. Inflammatory Bowel Diseases 2019;25:1957-65. [DOI: 10.1093/ibd/izz088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
8 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
9 Carchman E. Crohn's Disease and the Risk of Cancer. Clin Colon Rectal Surg 2019;32:305-13. [PMID: 31275078 DOI: 10.1055/s-0039-1683923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol 2019;23:3-13. [PMID: 30701345 DOI: 10.1007/s10151-019-1926-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
11 Gatenby G, Glyn T, Pearson J, Gearry R, Eglinton T. The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. Colorectal Dis 2021. [PMID: 34041848 DOI: 10.1111/codi.15756] [Reference Citation Analysis]
12 Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S; New York Crohn’s and Colitis Organization. Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:872-880.e1. [PMID: 31302306 DOI: 10.1016/j.cgh.2019.06.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]